| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4c3c65b018ce7acd6572dcfe1fbf8e0c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_61c0f034a14591eb608820b50d9fcb86 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16023
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5258
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04 |
| filingDate |
2004-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2009-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72a83d3701ca586724d1c8df9f956cf0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9916cf8b5e133e6e3a8257a270844943
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2bd14575b4b14a2390fc5fd8f3dd81fe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_591418b58a71d0ad706463cedb91e52a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19f4f78712b05c0d71b3540e91999fdc |
| publicationDate |
2009-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7479553-B2 |
| titleOfInvention |
Nucleic acids encoding mutant disulfide bond-stabilized human immunodeficiency virus type 1 (HIV-1) gp140 envelope glycoproteins |
| abstract |
This invention provides a DNA which upon transcription produces an RNA encoding a modified HIV-1 gp140 polypeptide, which polypeptide upon cleavage produces a modified gp120 and a modified ectodomain of gp41 which together form a complex exhibiting enhanced binding to HIV-1 neutralizing antibodies and reduced binding to HIV-1 non-neutralizing antibodies, wherein the modifications comprise an A492C mutation in gp120 and a T596C mutation in gp41, said mutations being numbered by reference to the HIV-1 isolate JR-FL, and resulting in a disulfide bond between gp120 and ectodomain gp41 which stabilizes the otherwise non-covalent gp120-gp41 interaction. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7939083-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011195089-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011076298-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010041875-A1 |
| priorityDate |
1999-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |